Key result
An early invasive approach reduced the 12-month composite endpoint of mortality, non-fatal MI, disabling stroke, and readmission in NSTEACS patients aged ≥75 years with elevated troponin.
Why the study?
Patients older than 75 years represent about 40% of CCU admissions with NSTEACS but have historically been underrepresented in randomised clinical trials.
Does an early invasive approach reduce the composite of mortality, non-fatal MI, disabling stroke, and readmission in elderly patients with NSTEACS?
Does an early invasive approach reduce the composite of mortality, non-fatal MI, disabling stroke, and readmission in elderly patients with NSTEACS?
This review discusses evidence that an early invasive approach may improve outcomes in elderly patients with NSTEACS, particularly those with elevated troponin.
Answers are grounded in this paper and cite their sources.
May support early invasive strategy in selected elderly NSTEACS; leaves open dedicated large RCTs for confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Savonitto et al. (2021) conducted a review in NSTEACS (n=313). Early invasive approach vs. Initially conservative approach was evaluated on composite primary 12-month endpoint (mortality, non-fatal myocardial infarction [MI], disabling stroke and readmission for cardiovascular causes or bleeding). An early invasive approach reduced the 12-month composite endpoint of mortality, non-fatal MI, disabling stroke, and readmission in NSTEACS patients aged ≥75 years with elevated troponin.
Synapse has enriched 10 related papers. Consider them for comparative context: